Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
Status:
Active, not recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of doxorubicin
in combination with pembrolizumab in subjects with metastatic or unresectable soft tissue
sarcoma. Based on previous studies, pembrolizumab may be an effective study treatment.